Soleno Therapeutics (SLNO) Operating Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Operating Expenses data on file, last reported at $63.3 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 38.44% year-over-year to $63.3 million in Q1 2026; TTM through Mar 2026 was $198.6 million, a 5.41% decrease from a year earlier, with the FY2025 full-year figure at $181.0 million, down 3.56% from the prior year.
• Operating Expenses for Q1 2026 stood at $63.3 million, up from $52.2 million in the prior quarter.
• Over the last five years, Operating Expenses for SLNO reached as high as $80.2 million in Q3 2024 and fell as low as $5.6 million in Q4 2022.
• Historically, Operating Expenses has averaged $29.3 million across 5 years, with a median of $23.5 million in 2024.
• Across the five-year window, Operating Expenses jumped 672.61% in 2024 and sank 45.25% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $5.6 million in 2022, then surged by 147.95% to $13.9 million in 2023, then soared by 324.99% to $59.1 million in 2024, then retreated by 11.78% to $52.2 million in 2025, then advanced by 21.42% to $63.3 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $63.3 million in Q1 2026, $52.2 million in Q4 2025, and $43.9 million in Q3 2025.